Biomarkers for pre-selection of patients for anti-IGF1R therapy
    18.
    发明授权
    Biomarkers for pre-selection of patients for anti-IGF1R therapy 有权
    用于预选抗IGF1R治疗的患者的生物标志物

    公开(公告)号:US07811562B2

    公开(公告)日:2010-10-12

    申请号:US11290687

    申请日:2005-11-30

    IPC分类号: A61K39/395

    摘要: The present invention provides methods for identifying patients whose cancers are likely to be responsive to IGF1R inhibitory anti-cancer therapy along with methods for treating such patients. Patients identified by a method of the present invention can be treated with any of several known IGF1R inhibitory agents including antibodies, small molecule inhibitors and anti-sense nucleic acids.

    摘要翻译: 本发明提供了用于鉴定癌症可能对IGF1R抑制性抗癌疗法有反应的患者以及用于治疗这些患者的方法的方法。 通过本发明的方法鉴定的患者可以用几种已知的IGF1R抑制剂中的任何一种来治疗,包括抗体,小分子抑制剂和反义核酸。

    Biomarkers for pre-selection of patients for anti-IGF1R therapy
    20.
    发明申请
    Biomarkers for pre-selection of patients for anti-IGF1R therapy 有权
    用于预选抗IGF1R治疗的患者的生物标志物

    公开(公告)号:US20060140960A1

    公开(公告)日:2006-06-29

    申请号:US11290687

    申请日:2005-11-30

    IPC分类号: A61K39/395

    摘要: The present invention provides methods for identifying patients whose cancers are likely to be responsive to IGF1R inhibitory anti-cancer therapy along with methods for treating such patients. Patients identified by a method of the present invention can be treated with any of several known IGF1R inhibitory agents including antibodies, small molecule inhibitors and anti-sense nucleic acids.

    摘要翻译: 本发明提供了用于鉴定癌症可能对IGF1R抑制性抗癌疗法有反应的患者以及用于治疗这些患者的方法的方法。 通过本发明的方法鉴定的患者可以用几种已知的IGF1R抑制剂中的任何一种来治疗,包括抗体,小分子抑制剂和反义核酸。